LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

32.71 4.47

Overview

Share price change

24h

Current

Min

30.35

Max

33.22

Key metrics

By Trading Economics

Income

-3.8M

-81M

EPS

-0.88

Profit margin

-18,560.15

Employees

437

EBITDA

-6.9M

-94M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+149.12% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-50M

3.2B

Previous open

28.24

Previous close

32.71

News Sentiment

By Acuity

63%

37%

336 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 May 2025, 23:59 UTC

Top News
Earnings

Naver 1Q Net Slumps on Higher Costs

8 May 2025, 23:39 UTC

Earnings

OCBC 1Q Net Down on Lower Interest Income

8 May 2025, 23:01 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 May 2025, 22:52 UTC

Earnings

REA Expects Annual Listings Growth Despite April Decline

8 May 2025, 22:46 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 May 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 May 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 May 2025, 23:30 UTC

Earnings

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 May 2025, 23:29 UTC

Earnings

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 May 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 May 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:01 UTC

Top News

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 May 2025, 22:28 UTC

Earnings

REA Expects FY 2025 Listings Growth of 1-2%

8 May 2025, 22:28 UTC

Earnings

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 May 2025, 22:27 UTC

Earnings

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 May 2025, 22:27 UTC

Earnings

REA Says April Residential Listings Fell by 11% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

149.12% upside

12 Months Forecast

Average 78.2 USD  149.12%

High 100 USD

Low 53 USD

Based on 11 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

336 / 382 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.